Envoy Medical (COCH) Price & Analysis

Compare

114 Followers

COCH Stock Chart & Stats

$0.72

-$0.05(-3.47%)

At close: Jan 08 4:00 PM EST

$0.72

-$0.05(-3.47%)

Day’s Range― - ―

52-Week Range$0.64 - $2.00

Previous CloseN/A

Volume61.49K

Average Volume (3M)390.88K

Market Cap

$20.24M

Enterprise Value$14.34M

Total Cash (Recent Filing)$3.56M

Total Debt (Recent Filing)$946.00K

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Apr 07, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding28,786,510

10 Day Avg. Volume185,535

30 Day Avg. Volume390,875

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-1.43

Price to Sales (P/S)119.42

P/FCF Ratio-1.42

Enterprise Value/Market Cap0.71

Enterprise Value/Revenue68.94

Enterprise Value/Gross Profit-23.43

Enterprise Value/Ebitda-0.73

Forecast

1Y Price Target

$6.00

Price Target Upside733.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.13

Revenue Forecast (FY)$250.00K

Bulls Say, Bears Say

Bulls Say

Market OpportunityThe company believes there is a significant market opportunity, with an estimated 25,000 to 30,000 adults in the U.S. getting cochlear implants annually by 2026, representing a market opportunity exceeding $750 million.

Product InnovationEnvoy has developed the Acclaim CI, a fully implanted cochlear implant that does not require any external component to be worn on the ear.

Regulatory ApprovalThe Acclaim CI received approval for its IDE application with the FDA to begin clinical testing and has already started trials with participants.

Bears Say

Development RisksEnvoy Medical’s devices still have long development and/or commercialization roads ahead, with high risks of clinical trials or commercial failures.

Financial PerformanceRevenue was ~$0 million, compared to estimates of $0.1 million, leading to a net loss of $9.1 million or EPS of $(0.46).

Envoy Medical News

Envoy Medical files to sell Class A common stock, no amount given

17:22 EST Envoy Medical (COCH) files to sell Class A common stock, no amount given Published first on...

2d ago

COCH

Envoy Medical Updates Investors on Strategic Plans

Envoy Medical ( ($COCH) ) has shared an update. Envoy Medical has released an updated investor presentation detailing...

4d ago

COCH

Envoy Medical Stockholders Approve Warrant Issuance

Envoy Medical ( ($COCH) ) has issued an announcement. On November 26, 2025, Envoy Medical, Inc. held a...

17d ago

COCH

Envoy Medical Faces Nasdaq Delisting Notice

Envoy Medical ( ($COCH) ) has issued an update. On November 19, 2025, Envoy Medical, Inc. received a...

25d ago

COCH

Envoy Medical Granted Nasdaq Listing Extension

An announcement from Envoy Medical ( ($COCH) ) is now available. On October 27, 2025, Envoy Medical announced...

2M ago

COCH

Envoy Medical’s Acclaim Cochlear Implant Trial: A Potential Game-Changer for Hearing Loss

Envoy Medical, Inc. Class A (($COCH)) announced an update on their ongoing clinical study. Study Overview: Envoy Medical,...

2M ago

COCH

Envoy Medical Raises $4 Million in Stock Offering

Envoy Medical ( ($COCH) ) has issued an update. On October 7, 2025, Envoy Medical entered into a...

2M ago

COCH

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Analyst updates, earnings reports, economic affairs lead the top stock market stories traders need to read on Wednesday. ...

2M ago

AMD

BLD

Why Is Envoy Medical Stock (COCH) Down 35% Today?

Envoy Medical stock was down on Wednesday alongside a registered direct offering for the shares. ...

2M ago

COCH

Envoy Medical Gains FDA Approval for Final Trial

An update from Envoy Medical ( ($COCH) ) is now available. On October 7, 2025, Envoy Medical announced...

2M ago

COCH

Envoy Medical Announces Securities Purchase Agreement

An update from Envoy Medical ( ($COCH) ) is now available. On September 22, 2025, Envoy Medical announced...

3M ago

COCH

Envoy Medical announces four new patents

Envoy Medical (COCH) announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US...

1y ago

COCH

Envoy Medical reports Q3 EPS (37c) vs. 13c last year.

Reports Q3 revenue $56,000 vs. $80,000 last year. “The progress and accomplishments of late have been extremely important...

1y ago

COCH

Envoy Medical announces publication on Acclaim CI

Envoy Medical (COCH) announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential...

1y ago

COCH

COCH FAQ

What was Envoy Medical, Inc. Class A’s price range in the past 12 months?

Envoy Medical, Inc. Class A lowest stock price was $0.64 and its highest was $2.00 in the past 12 months.

What is Envoy Medical, Inc. Class A’s market cap?

Envoy Medical, Inc. Class A’s market cap is $20.24M.

When is Envoy Medical, Inc. Class A’s upcoming earnings report date?

Envoy Medical, Inc. Class A’s upcoming earnings report date is Apr 07, 2026 which is in 108 days.

How were Envoy Medical, Inc. Class A’s earnings last quarter?

Envoy Medical, Inc. Class A released its earnings results on Nov 10, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.11.

Is Envoy Medical, Inc. Class A overvalued?

According to Wall Street analysts Envoy Medical, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Envoy Medical, Inc. Class A pay dividends?

Envoy Medical, Inc. Class A does not currently pay dividends.

What is Envoy Medical, Inc. Class A’s EPS estimate?

Envoy Medical, Inc. Class A’s EPS estimate is -0.24.

How many shares outstanding does Envoy Medical, Inc. Class A have?

Envoy Medical, Inc. Class A has 28,786,510 shares outstanding.

What happened to Envoy Medical, Inc. Class A’s price movement after its last earnings report?

Envoy Medical, Inc. Class A reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -0.285%.

Which hedge fund is a major shareholder of Envoy Medical, Inc. Class A?

Currently, no hedge funds are holding shares in COCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Envoy Medical, Inc. Class A

Envoy Medical (COCH) is a pioneering company in the medical device sector, specializing in innovative solutions for hearing restoration. The company is best known for its flagship product, the Coclear Implant System, which provides a unique approach to treating severe to profound hearing loss. Envoy Medical operates within the healthcare industry, focusing on the development and commercialization of advanced implantable devices designed to improve the quality of life for individuals with hearing impairments.

Envoy Medical (COCH) Earnings & Revenues

Historic Earnings Reports

COCH Stock 12 Month Forecast

Average Price Target

$6.00

▲(733.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,1.209230769230769,1.6084615384615384,2.0076923076923077,2.4069230769230767,2.8061538461538458,3.2053846153846153,3.6046153846153843,4.003846153846153,4.403076923076922,4.802307692307691,5.20153846153846,5.600769230769231,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,1.209230769230769,1.6084615384615384,2.0076923076923077,2.4069230769230767,2.8061538461538458,3.2053846153846153,3.6046153846153843,4.003846153846153,4.403076923076922,4.802307692307691,5.20153846153846,5.600769230769231,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,1.209230769230769,1.6084615384615384,2.0076923076923077,2.4069230769230767,2.8061538461538458,3.2053846153846153,3.6046153846153843,4.003846153846153,4.403076923076922,4.802307692307691,5.20153846153846,5.600769230769231,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.445,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.773,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.805,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >